Bio-techne Corporation dividend yield calculator – BIO-TECHNE Corporation Surges on Dividend Announcement Before Market Opening

🌥️Trending News

BIO-TECHNE Corporation, also known as Bio-Techne Co., is a leading global life sciences company that provides innovative solutions for the research and clinical diagnostic markets. The company’s diverse portfolio includes products and services in areas such as protein analysis, cell culture, immunoassays, and genetic analysis. On Wednesday, Bio-Techne Co. experienced a surge in its stock value before the market opened due to the company’s announcement of a dividend payout. This news was well received by investors and analysts, leading to a significant increase in the company’s stock price. The dividend announcement comes as a positive development for BIO-TECHNE CORPORATION ($NASDAQ:TECH) and its shareholders. It highlights the company’s strong financial performance and commitment to delivering value to its investors. This move also demonstrates the company’s confidence in its future growth prospects and ability to generate strong returns for its shareholders. The announcement of a dividend payout is reflective of the company’s overall financial health and stability.

With consistent revenue growth and a solid balance sheet, BIO-TECHNE CORPORATION is well-positioned to continue its investments in research and development, expand its product portfolio, and pursue strategic acquisitions. This not only benefits the company but also adds value for its shareholders in the long term. In addition to its dividend announcement, BIO-TECHNE CORPORATION has also been making significant strides in driving innovation and expanding its global presence. The company recently acquired Asuragen, a molecular diagnostics company, to further enhance its position in the diagnostics market. This acquisition is expected to strengthen BIO-TECHNE’s product offerings and increase its market share. Overall, the surge in BIO-TECHNE CORPORATION’s stock value on Wednesday reflects investor confidence in the company’s growth potential and its commitment to providing value to its shareholders. With a strong financial position and a track record of consistent performance, the company is well-equipped to continue its growth trajectory and create value for its investors in the years to come.

Dividends – Bio-techne Corporation dividend yield calculator

BIO-TECHNE Corporation, a leading global life sciences company, made a significant announcement this morning that sent its stock surging before the market opening. The company has declared its annual dividend per share for the next three years, which has been consistent at 0.32 USD in the past three years. This announcement shows the company’s commitment to its shareholders, as it plans to continue providing them with dividends in the coming years. The current dividend yield for BIO-TECHNE Corporation for 2022, 2023, and 2024 is estimated to be 0.34%, 0.42%, and 0.34% respectively, with an average dividend yield of 0.37%. This is an increase from the previous year’s dividend yield of 0.32%, indicating the company’s growth and stability. Investors and analysts have reacted positively to this news, resulting in a surge in the company’s stock price before the market opening. This increase in dividends not only benefits shareholders but also reflects the company’s strong financial position and positive outlook for the future.

BIO-TECHNE Corporation has a long-standing history of paying dividends to its shareholders, which demonstrates its commitment to providing consistent returns to investors. This announcement also reflects the company’s confidence in its ability to generate sustainable cash flows and maintain a stable financial position in the coming years. Furthermore, this dividend announcement is in line with the company’s overall strategy of driving growth and creating value for its shareholders. It also showcases BIO-TECHNE Corporation’s strong financial discipline and prudent approach towards managing its cash flow. In conclusion, BIO-TECHNE Corporation’s recent dividend announcement has not only pleased its shareholders but has also provided a positive outlook for the company’s future prospects. With a consistent track record of paying dividends and a strong financial position, BIO-TECHNE Corporation remains a reliable choice for investors looking for stable returns.

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Bio-techne Corporation. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Bio-techne Corporation. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Bio-techne Corporation. More…

Key Ratios Snapshot

Some of the financial key ratios for Bio-techne Corporation are shown below. More…

Stock Price

BIO-TECHNE Corporation, a leading provider of life science tools and services, saw a surge in its stock price on Monday following the announcement of a dividend before the market opening. The company’s stock opened at $69.59 and closed at $70.39, representing a 2.49% increase from the previous day’s closing price of $68.68. Investors were pleased with the news of a dividend, as it indicates that the company is generating strong profits and has confidence in its financial position. This dividend announcement also reflects the company’s commitment to providing returns to its shareholders. BIO-TECHNE Corporation has a strong track record of consistent growth and profitability, making it an attractive choice for investors. In addition to its robust financial performance, BIO-TECHNE Corporation has also been making strategic investments to enhance its product portfolio and expand its global reach.

This acquisition is expected to drive further growth for BIO-TECHNE Corporation in the coming years. The market reaction to the dividend announcement is a testament to the confidence investors have in the company’s future prospects. With its strong financials, strategic investments, and commitment to shareholder returns, BIO-TECHNE Corporation is well-positioned for continued success in the rapidly evolving biotechnology industry. In conclusion, the surge in BIO-TECHNE Corporation’s stock price following the dividend announcement is a positive sign for both existing and potential investors. This move is indicative of the company’s strong financial performance and strategic initiatives, making it an attractive choice in the biotechnology sector. Live Quote…

Analysis – Bio-techne Corporation Stock Fair Value Calculation

After conducting a thorough analysis of BIO-TECHNE CORPORATION, I have found that the company has strong fundamentals. The company specializes in life science tools and diagnostics, and has a diverse portfolio of products and services. This has allowed the company to maintain a stable revenue stream even during economic downturns. Based on our proprietary Valuation Line, the fair value of BIO-TECHNE CORPORATION’s share is estimated to be around $97.5. However, the current market price of $70.39 represents a discount of approximately 27.8% to its fair value. This indicates that the stock is currently undervalued and presents a potential buying opportunity for investors. In addition to its strong fundamentals, BIO-TECHNE CORPORATION also has a track record of consistent growth and profitability. The company has consistently increased its revenues and earnings over the years, which is a positive sign for investors. Furthermore, BIO-TECHNE CORPORATION has a strong financial position with a healthy balance sheet and low debt burden. This provides the company with the flexibility to invest in research and development, as well as pursue potential acquisitions to drive future growth. In conclusion, after analyzing all aspects of BIO-TECHNE CORPORATION, I believe that the stock is undervalued at its current market price. With its strong fundamentals, consistent growth, and solid financial position, I am confident in the company’s long-term prospects and potential for shareholder returns. More…

Peers

In the realm of biotechnology, there is fierce competition between companies to provide the best products and services. Among these companies is Bio-Techne Corp, which competes against Proteomics International Laboratories Ltd, AEterna Zentaris Inc, AXIM Biotechnologies Inc, and others. While each company has its own strengths and weaknesses, Bio-Techne Corp has been able to distinguish itself through its innovative products and cutting-edge technology. As the biotechnology landscape continues to evolve, it will be interesting to see how these companies adapt and change in order to stay ahead of the competition.

– Proteomics International Laboratories Ltd ($ASX:PIQ)

Proteomics International Laboratories Ltd is a company that specializes in providing proteomics services. Its market cap as of 2022 was 110.87M, and its ROE was -75.41%. The company’s main services include proteomics research, biomarker discovery, and protein quantification. Proteomics International Laboratories Ltd has a strong focus on quality and customer service, and has a team of experienced scientists that are dedicated to helping their clients achieve success.

– AEterna Zentaris Inc ($TSX:AEZS)

Aeterna Zentaris is a Canadian biopharmaceutical company engaged in the discovery, development, and commercialization of therapeutic drugs for the treatment of cancer and endocrine disorders. As of 2022, the company had a market capitalization of $25.01 million and a return on equity of -14.54%. The company’s products include the cancer drug Macrilen, which is approved for the treatment of acromegaly, and the endocrine disorder drug Zoptarelin Doxorubicin, which is in clinical development for the treatment of breast cancer.

– AXIM Biotechnologies Inc ($OTCPK:AXIM)

AXIM Biotechnologies Inc is a clinical stage pharmaceutical company focused on the development of cannabinoid-based therapeutics. The company’s products are based on proprietary technology platforms that utilize purified cannabinoids to address specific disease conditions.

The company’s market cap is 10.55M as of 2022. The company’s ROE is 223.83%.

The company’s products are based on proprietary technology platforms that utilize purified cannabinoids to address specific disease conditions. The company is focused on the development of cannabinoid-based therapeutics to treat pain, inflammation, anxiety, and other conditions.

Summary

Bio-Techne Co. (NASDAQ: TECH) saw a surge in its stock price on Wednesday after announcing a quarterly dividend of $0.32 per share. This increase in share value can be attributed to the company’s strong financial performance and positive outlook. Its stock has been steadily rising over the past year and analysts are optimistic about its future growth potential. This dividend announcement further solidifies the company’s position as a stable and attractive investment option for investors looking to capitalize on the promising biotech sector.